(IN BRIEF) Fresenius Kabi announces FDA approval of Tyenne® (tocilizumab-aazg), the first tocilizumab biosimilar offering both IV and subcutaneous formulations.…
(IN BRIEF) AstraZeneca's new drug application (NDA) for capivasertib, in combination with Faslodex, has been accepted and granted Priority Review…